Ask AI
ProCE Banner Series

Learn about a Treatment Option for Adults with R/R DLBCL After ≥2 Prior Lines of Systemic Therapy

This presentation will examine unmet needs in relapsed/refractory diffuse large B cell lymphoma and review a treatment option for adults who have received more than two prior lines of systemic therapy. This program is sponsored by Pfizer.

Key Takeaway

  • Upon completion of this presentation, attendees will be able to identify key unmet needs in relapsed/refractory diffuse large B cell lymphoma and evaluate a treatment option for patients in the third line and beyond.

All Events

Learn about a Treatment Option for Adults with R/R DLBCL After ≥2 Prior Lines of Systemic Therapy

Upcoming Events

May

20

2026

12:15 PM - 1:00 PM Eastern Time (ET)

Virtual

Acknowledgement

Sponsored By

Pfizer